| 敖 曼,肖 旭,闫 妍,时 岩,吕喜英.沙利度胺对原发性肝癌介入后血管内皮生长因子及生存质量的影响[J].现代生物医学进展英文版,2017,17(25):4928-4931. |
| 沙利度胺对原发性肝癌介入后血管内皮生长因子及生存质量的影响 |
| Effects of Thalidomide on VEGF and Quality of Life in Patients with Primary Hepatocellular Carcinoma after Transcatheter Arterial Chemoembotization |
| Received:March 02, 2017 Revised:March 30, 2017 |
| DOI：10.13241/j.cnki.pmb.2017.25.031 |
| 中文关键词: 原发性肝癌 沙利度胺 血管生长因子 生存质量 肝动脉栓塞化疗 |
| 英文关键词: Hepatocelldiar carcinoma Thalidomide Vascular endothelial growth factor Quality of life Transcatheter arterial chemoembolization |
| 基金项目: |
|
| Hits: 313 |
| Download times: 188 |
| 中文摘要: |
| 摘要 目的：探讨沙利度胺对原发性肝癌（HCC）介入后血管内皮生长因子（VEGF）及生存质量的影响。方法：将2014年1月至2016年1月期间我院收治的拟行肝动脉栓塞化疗（TACE）的HCC患者60例按照随机数字表法分为A、B两组，各30例。A组患者采用TACE+沙利度胺治疗，每晚200 mg，口服一个月；B组患者单行TACE治疗。分别于治疗前、治疗后3周检测两组患者的VEGF水平，于治疗前、治疗后1个月应用生存质量评分量表（QOL）评价患者生存质量，并比较两组患者治疗前后的体重及治疗过程中的不良反应。结果：治疗前两组患者血清VEGF水平差异无统计学意义(P>0.05)。治疗后两组患者VEGF水平均较治疗前升高，其中A组患者治疗后VEGF水平显著低于B组患者(P＜0.01)。治疗前两组患者QOL分数和体重比较差异无统计学意义(P>0.05)。而治疗后两组患者的QOL分数较治疗前均有所降低，但A组患者的QOL分数显著高于B组患者(P＜0.05)，而两组患者治疗后的体重无统计学差异(P>0.05)。A组30例患者中有1例（3.33%）患者因严重嗜睡、2例（6.67%）患者因严重口腔干燥而终止口服沙利度胺，其余27例患者均能耐受。结论：沙利度胺联合TACE方法治疗HCC可降低VEGF水平和改善癌症患者的生存质量，值得在临床上推广使用。 |
| 英文摘要: |
| ABSTRACT Objective: To investigate the effects of thalidomide on vascular endothelial growth factor(VEGF) and quality of life in patients with primary hepatocellular carcinoma after transcatheter arterial chemoembotization. Methods: A total of 60 patients with HCC, who were treated with transcatheter arterial chemoembolization (TACE) in Affiliated Hospital of Chengde Medical University from Jan- uary 2014 to January 2016, were randomly divided into group A（n=30）and group B（n=30）. Group A was treated with Thalidomide in combination with TACE, oral 200 mg every night for 1 month; group B was treated with TACE alone. The levels of VEGF in the two groups were detected before treatment and 3 weeks after treatment; the quality of life of patients before treatment and 1 month after treat- ment was evaluated by quality of life scale (QOL); the weight of two groups before and after treatment and adverse reactions during treat- ment were compared. Results: There was no significant difference in VEGF levels between the two groups before treatment (P>0.05). Af- ter treatment, the levels of VEGF in the two groups were higher than those before treatment, and the VEGF levels in the group A was sig- nificantly lower than that in the group B, the difference was statistically significant (P<0.01). There was no significant difference in QOL score and body weight between the two groups before treatment (P>0.05). The QOL scores of the two groups after treatment were lower than those before treatment, but the QOL scores of patients in group A were significantly higher than those in group B (P<0.05). There was no significant difference in weight between the two groups before and after treatment (P>0.05). In group A, 1 patients (3.33%) had severe somnolence, 2(6.67%) patients stopped taking thalidomide due to severe dry mouth, and the remaining 27 patients were able to tolerate. Conclusion: Thalidomide combined with TACE in the treatment of patients with HCC can reduce the levels of VEGF and im- prove the quality of life of cancer patients, which is worthy to be popularized in clinic. |
|
View Full Text
View/Add Comment Download reader |
| Close |
